Deprenyl in Parkinson's Disease

Deprenyl is a selective inhibitor of brain MAO‐B in the long‐term treatment of Parkinsons's disease.

“…This suggests that the inhibitor does not further accumulate in the brain after the first few days, presumably reflecting a rapid metabolism to amphetamine and methamphetamine (Reynolds, Elsworth, Blau, Sandler, Lees & Stern, 1978). These results are consistent with those of , who show no clinically significant change in tolerance to tyramine after 18 months treatment and they serve to underline the safety of the drug in clinical practice (Birkmayer et al, 1977;Lees et al, 1977 Received October 8,1979 …”

Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa.

“…The beneficial effect of nocturnal dosing with levodopa on morning performance suggests that its hypnotic-like effect is secondary to improvement in control of Parkinson's disease. Lees et al (1977) found that difficulty in turning voluntarily during the night was responsive to dopaminergic therapy. The patient's improved ability to turn in bed may allow a more comfortable position to be adopted.…”

Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat

“…Thus AGN 1135 potentially could be a useful drug like selegiline (Birkmayer et al, 1977;Lees et al, 1977) for potentiating the anti-Parkinson action of L-DOPA.…”